AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02199613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment simplification
Description: Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
Study NCT01338883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc 100 mg
Description: 100 mg CVC plus Truvada
Study NCT01338883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc 200 mg + Truvada
Description: 200 mg CVC plus Truvada
Study NCT01338883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustiva + Truvada
Description: Sustiva plus Truvada
Study NCT04090047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 oral tablets in 5mg and 25mg provided for a 30mg dose
Study NCT04090047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg oral solution administered as 20 milliliters(mL) (10 mg/mL)
Study NCT02949011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Tablets taken orally
Study NCT02949011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Baloxavir Marboxil
Description: Matching tablets taken orally
Study NCT02949011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Baloxavir Marboxil
Description: Matching tablets taken orally
Study NCT02949011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Capsules taken orally
Study NCT02560441 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: chemotherapy followed by radiotherapy
Study NCT02560441 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: radiotherapy followed by chemotherapy
Study NCT02560441 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPGDP regimen chemotherapy
Study NCT01991665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Digital examination
Study NCT02949011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Oseltamivir
Description: Matching placebo capsules taken orally
Study NCT02949011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Oseltamivir
Description: Matching placebo capsules taken orally
Study NCT04046640 — intervention group
Intervention type: DEVICE
Intervention: Infrared thermal imaging
Description: Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a NEC InfRec R450 infrared thermal imaging camera~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian.
Study NCT01991665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sonography evaluation
Study NCT00825136 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation
Description: Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.
Study NCT00825136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation
Description: Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.
Study NCT00825136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biofeedback (finger temperature biofeedback)
Description: Participants were asked to log in the system to keep the muscle relaxation program plus finger temperature biofeedback every day and complete some self-rating scales on browser every week.
Study NCT03659474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compression
Description: compression by Game Ready
Study NCT03659474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice pack
Description: cryotherapy for ice pack
Study NCT03659474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion
Description: immersion therapy
Study NCT02053675 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vasopressin infusion
Study NCT02980874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suprachoroidal CLS-TA
Description: suprachoroidal injection of CLS-TA
Study NCT04874467 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive periodontal therapy
Description: A complete professional prophylaxis session will be performed, which includes ultrasound debridement, scaling with curettes and dental polishing with a rubber cup. On the other hand, in implants affected by mucositis, supra and sub-gingival debridement will be performed using a combination of ultrasound with a titanium tip and titanium curettes.~All patients will receive personalized hygiene instructions. Patients will be instructed to brush their implants twice daily using the modified Bass technique with a medium-hard manual toothbrush and low-abrasive toothpaste. In addition, they will be taught to use specific interproximal brushes. If access with an interdental brush is not possible, flossing will be indicated. Oral hygiene instructions will be reviewed at each visit.
Study NCT01546844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participation in Care4Life
Description: Text message service to aid patients with self-management of type II Diabetes Mellitus. Includes online access to patient data and management of health goals.
Study NCT03737292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: The intercostal blocks will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions. On average, 5-6 intercostal spaces will be injected with 4-5 ml of local anesthetic at each level.
Study NCT03737292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The intercostal injections of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml total will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions.
Study NCT01710969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual intervention
Description: 34 weekly sessions of cognitive-behavioral Coping Power intervention, delivered in an individual one-to-one format
Study NCT01710969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Intervention
Description: 34 weekly sessions of Coping Power intervention, delivered in a small group format (6 children per gorup)
Study NCT00144391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Testosterone gel
Description: 2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
Study NCT00144391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Testosterone gel
Description: 2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
Study NCT02034968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab: 200mg,IV once a week during chemotherapy.
Study NCT02685189 — intervention group
Intervention type: OTHER
Intervention: Previous exposure to stannsoporfin
Description: No intervention in this protocol
Study NCT01025258 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Frequent Scheduled CF clinic visits
Description: Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacist
Study NCT03376152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electric Kettle Promotion
Description: Provision of free electric kettles and promotional materials/information
Study NCT03882502 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: anodal transcranial direct current stimulation (tDCS)- accompanied naming therapy or sham stimulation
Description: anodal tDCS or sham stimulation will be combined with an intensive naming training and the number of items that could be named will be assessed immediately after the intervention.
Study NCT03882502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (tDCS)- accompanied naming therapy or sham stimulation
Description: anodal tDCS or sham stimulation will be combined with an intensive naming training and the number of items that could be named will be assessed immediately after the intervention.
Study NCT01025258 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: frequent telephone calls to patients pre and post visits to the clinic
Description: Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
Study NCT00635674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP device - REMstar Plus, Respironics, Murrysville, USA
Description: continuous positive airway pressure device with heated humidification
Study NCT00635674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP device - REMstar Plus, Respironics, Murrysville, USA
Description: continuous positive airway pressure device with heated humidification
Study NCT00730769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single arm (ganciclovir and valganciclovir)
Description: Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
Study NCT01211470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: Active Comparator: Daptomycin.
Study NCT01211470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMX-30063-investigational drug
Description: Experimental: PMX-30063
Study NCT02758990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Subjects will be asked to increase vitamin A intake by 8000 International Units per day.
Study NCT02758990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Subjects will be asked to increase vitamin B6 intake by 50 mg per day.
Study NCT02758990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Subjects will be asked to increase vitamin C intake by 500 mg per day.
Study NCT01541371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
Study NCT02758990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
Study NCT04567524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LYN-005
Description: LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
Study NCT04567524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LYN-005
Description: LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
Study NCT05233514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise in addition to Metformin treatment
Description: The aerobic exercises were walking on the treadmill for 30 minutes at a 0% slope, including three phases: the warming-up phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of Maximum Heart Rate, MHR), the actual phase, which consisted of walking on the treadmill for 20 min at moderate intensity (60 -70% of MHR) and the cooling phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of MHR). The MHR was calculated according to the equation (210- age in years). Both the AEM and M groups received metformin 1,500 mg daily for a further 12 weeks.
Study NCT05233514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise in addition to Metformin treatment
Description: The aerobic exercises were walking on the treadmill for 30 minutes at a 0% slope, including three phases: the warming-up phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of Maximum Heart Rate, MHR), the actual phase, which consisted of walking on the treadmill for 20 min at moderate intensity (60 -70% of MHR) and the cooling phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of MHR). The MHR was calculated according to the equation (210- age in years). Both the AEM and M groups received metformin 1,500 mg daily for a further 12 weeks.
Study NCT03071965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor (CNTF)
Description: The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.
Study NCT03071965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery to implant device for NT-501
Study NCT03071965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Sham surgery
Study NCT04274595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic antiretroviral
Description: 200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days
Study NCT02953184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: 35mg/m2 iv drop during the first 4 cycles every three week
Study NCT02953184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2 IV drop during the first 4 cycles every three week
Study NCT02953184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600mg/m2 IV drop during the first 4 cycles every three week
Study NCT02527148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OtisMed® ShapeMatch® Technology
Description: The appropriate Stryker ShapeMatch® Cutting Guides will be used to guide the surgeons bone resections. The surgeon will implant the knee prostheses following the surgical protocol for Triathlon® Knee System with OtisMed® ShapeMatch® Technology
Study NCT02527148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Precision Knee Navigation
Description: Stryker PrecisioN Knee (4.0) Navigation System, comprising of computer hardware and software and associated instrumentation, will be used for intra-operative alignment and orientation of implant. Navigation trackers will be secured to the femur and tibia and registration of the limb will be undertaken according to the PrecisioN Knee System surgical technique.Femoral and tibial resections, followed by device implantation, will be performed according to the Triathlon Knee System Surgical Protocol.
Study NCT02527148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Study NCT02527148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Triathlon® Total Knee System
Description: Prosthetic components to be implanted including~* Triathlon® Cruciate Retaining (CR) Total Knee System (cemented), including Femoral Component and Primary Tibial Baseplate;~* Triathlon® Cruciate Substituting (CS) X3® polyethylene insert;~* Triathlon® X3 Patella (asymmetric) - treated selectively by surgeon.
Study NCT02953184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 100mg/m2 IV drop during the last 4 cycles every three week
Study NCT02466165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Study NCT02953184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Description: 100mg/m2 IV drop during the last 4 cycles every three week
Study NCT03633565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil (Phosphodiesterase inhibitors)
Description: tablet 25mg
Study NCT02758990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.
Study NCT02758990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Subjects will be asked to increase vitamin E intake by 400 International Units per day.
Study NCT02758990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broccoli
Description: Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.
Study NCT03633565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone (Steroids)
Description: tablet 20 mg
Study NCT03633565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation
Description: stem cell transplantation intramuscular
Study NCT03541655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl
Description: 0.25% Bupivacaine HCl
Study NCT03541655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 0.25% Bupivacaine HCl
Study NCT03541655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F14 (celecoxib)
Description: Celecoxib in novel drug delivery system (BEPO™)
Study NCT02758990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinach
Description: Subjects will be asked to increase spinach intake by 8 fluid ounces (\~30 grams) per day.
Study NCT02758990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
Study NCT02953184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexrazoxane (DZR)
Description: DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.
Study NCT01120379 — intervention group
Intervention type: DEVICE
Intervention: XIENCE V® EECSS
Description: Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
Study NCT00546793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: veltuzumab
Description: veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.
Study NCT03445754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TVS
Description: Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
Study NCT03445754 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TVS
Description: Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
Study NCT00881361 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: systemic chemotherapy
Study NCT00881361 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: axillary lymph node dissection
Study NCT00881361 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: neoadjuvant therapy
Study NCT00881361 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: sentinel lymph node biopsy
Study NCT00881361 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery
Study NCT02953184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin B
Description: Vitamin B will be administrated for protecting HFS in PLD group
Study NCT02953184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
Study NCT02953184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Conserved Surgery
Description: Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy
Study NCT02953184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast Conserved Surgery
Description: Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy